Kura Oncology, Inc. (KURA) Earnings Call Transcripts
Kura Oncology, Inc.'s Latest Earnings Call - June 12, 2026
In the Q2 2026 earnings call, Kura Oncology, Inc. (KURA) reported significant advancements in its ziftomenib program for treating acute myeloid leukemia (AML). The company highlighted impressive clinical results from the KOMET-007 trial, particularly a 94% complete response (CR) rate in NPM1 mutated patients, with a median overall survival (OS) not yet reached. Management maintained guidance for the ongoing Phase III KOMET-017 trial, emphasizing its potential to expand the addressable market from $350-$400 million to $7 billion if successful. Revenue and earnings figures were not disclosed in the transcript, but the strong clinical data could drive stock performance positively in the near term.
Reported metrics
| Metric | Value |
|---|---|
| Complete Response Rate (NPM1) | 94% (beat) |
| Overall Survival Rate (NPM1) | 94% at 12 months (beat) |
| Median Time to CR | 1.5 months (positive) |
| Induction Mortality Rate | 2% (positive) |
| MRD Negativity Rate | 56% (positive) |
| Total Addressable Market (U.S.) | $350-$400 million (positive) |
Guidance from management
Management remains optimistic about the ongoing Phase III KOMET-017 trial, which is designed to generate clinically meaningful data for global markets. They expect the trial to support accelerated approval based on the promising results from the KOMET-007 trial.
What management said
I mean it's certainly still evolving. You'd see that it's going to be at worst, about 24 months is what it looks like at this point. These patients are, in general, very successful on treatment, getting into a response and then staying on treatment with the monotherapy once they're in their response. So we don't have the exact answer yet because, thankfully, for these patients, their treatment is still ongoing, and w...
Great. And let me just clarify, those of you who want to ask a question, if you'd like to ask a question and a follow-up question, please feel free. We're going to limit it to just one question and one follow-up, but you're welcome to get back in the queue. But going forward, one and one is fine. . Stephan, next question.
What analysts pressed on
Analysts expressed concerns regarding the long-term durability of responses and how MRD negativity will influence treatment decisions, particularly in patients who may require transplantation. There were questions about the potential for ziftomenib to be used in relapsed settings after frontline therapy.
Main topics on the call
- Strong Clinical Efficacy — The KOMET-007 trial demonstrated a 94% complete response (CR) rate in NPM1 mutated patients, with median overall survival not yet reached. Management stated, "the overall survival rate was an impressive 94% at 12 months,...
- Safety Profile Consistency — The combination of ziftomenib with 7+3 showed a safety profile consistent with historical data, with no additional myelosuppression observed. Management noted, "the addition of ziftomenib does not result in delayed count...
- Ongoing Registrational Trial — The Phase III KOMET-017 trial is designed to evaluate ziftomenib in combination with intensive chemotherapy. Management expressed confidence, stating, "the data support the ongoing registrational Phase III trial, KOMET-0...
- Market Potential Expansion — Management indicated that successful outcomes from the KOMET-017 trial could expand the total addressable market significantly to up to $7 billion. They stated, "we're optimistic that if the KOMET-017 studies are success...
Read the full Kura Oncology, Inc. transcript (June 12, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 60 calls on record spanning January 16, 2020 to July 27, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 60 Kura Oncology, Inc. earnings call transcripts on record, spanning January 16, 2020 to July 27, 2026. Based on this history, Kura Oncology, Inc. reports quarterly. The most recent call on file is dated July 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- KURA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 60
- First call
- January 16, 2020
- Most recent
- July 27, 2026
- Reporting cadence
- quarterly